Figure 4.

FKBP51 activated EMT through the NF-κB pathway. (A) GFP-FKBP51 K1 cells were treated with NF-κB pathway inhibitor PDTC (20 µM) for 24 h and the cells' migration and invasive capacities were determined using the transwell assay. (B) EMT-associated proteins TGF-β1, β-catenin, N-cadherin, MMP9 of K1 cells and TGF-β1, Vimentin, N-cadherin, MMP9 of TPC-1 cells were detected by western blotting. (C) FKBP51-overexpressing K1 cells were treated with NF-κB inhibitor PDTC (20 mM) for 24 h and expression of TGF-β1, β-catenin, N-cadherin and MMP9 was compared with control group was detected. *P<0.05; **P<0.01; ***P<0.001. FKBP51, FK506 binding protein 51; GFP, green fluorescent protein; vec, vector; MMP, matrix metalloproteinase; EMT, epithelial mesenchymal transition.